Mark McClellan - Johnson Johnson Independent Director

JNJ Stock  USD 157.96  2.19  1.41%   

Director

Dr. Mark B. McClellan, M.D., Ph.D. is an Independent Director of the Company. He became the inaugural Director of the DukeRobert J. Margolis, MD, Center for Health Policy and the Margolis Professor of Business, Medicine and Policy at Duke University in January 2016. He is also a faculty member at Dell Medical School at The University of Texas in Austin. Previously, he served from 2007 to 2015 as a Senior Fellow in Economic Studies and as Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. Dr. McClellan served as Administrator of the Centers for Medicare Medicaid Services for the U.S. Department of Health and Human Services from 2004 to 2006 and as Commissioner of the U.S. Food and Drug Administration from 2002 to 2004. He served as a member of the Presidents Council of Economic Advisers and as senior director for healthcare policy at the White House from 2001 to 2002 and, during President Bill Clintons administration, held the position of Deputy Assistant Secretary for Economic Policy for the Department of the Treasury. Dr. McClellan previously served as an associate professor of economics and medicine with tenure at Stanford University, where he also directed the Program on Health Outcomes Research. Dr. McClellan is the founding chair and a current board member of the ReaganUdall Foundation for the Food and Drug Administration, is a member of the National Academy of Medicine and chairs the Academys Leadership Consortium for Value and ScienceDriven Health Care, and cochairs the guiding committee of the Health Care Payment Learning and Action Network. since 2013.
Age 57
Tenure 11 years
Professional MarksPh.D
Address One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Phone732 524 0400
Webhttps://www.jnj.com
McClellan has received the Kenneth J. Arrow Award twice for Outstanding Research in Health Economics. A 1985 graduate of the University of Texas at Austin, Dr. McClellan earned his MD degree at the Harvard UniversityMassachusetts Institute of Technology Division of Health Science and Technology, and his MPA at the Kennedy School of Government at Harvard. He earned his PhD in Economics at MIT and completed his residency in internal medicine at Brigham and Women Hospital in Boston.

Johnson Johnson Management Efficiency

The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to hike to 0.26 this year. Return On Assets is expected to hike to 0.13 this year. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).
The company has 30.43 B in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.4, which is typical for the industry and considered as normal. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Meryl ZausnerSeres Therapeutics
61
Peter HuttSeres Therapeutics
80
Charles McDermottEquillium
45
Heidi FieldsAgilent Technologies
60
Donald KufeMadrigal Pharmaceuticals
69
Paul ClarkAgilent Technologies
72
George ScangosAgilent Technologies
72
Marc LavineEquillium
N/A
Tadataka YamadaAgilent Technologies
74
William ReardonMadrigal Pharmaceuticals
68
Robert WilsonMadrigal Pharmaceuticals
75
Werner CautreelsSeres Therapeutics
N/A
David MilliganMadrigal Pharmaceuticals
77
Kurt GravesSeres Therapeutics
50
Richard KenderSeres Therapeutics
62
James DalyMadrigal Pharmaceuticals
N/A
David BerrySeres Therapeutics
37
Gregory BeharSeres Therapeutics
48
Stephen ConnellyEquillium
42
AnnChristine Hvittfeldt23Andme Holding Co
49
Mala AnandAgilent Technologies
53
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 141700 people. Johnson Johnson (JNJ) is traded on New York Stock Exchange in USA. It is located in One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 and employs 131,900 people. Johnson Johnson is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Duane Arsdale, Treasurer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Jasmina Brooks, President Webster
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Nadja West, Independent Director
Mark Larkins, Worldwide Secretary
Vanessa Broadhurst, Executive Vice President Global Corporate Affairs
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Tom Cavanaugh, Company Medicine
D Davis, Independent Director
Anne Mulcahy, Lead Independent Director
Ian Davis, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Mark Weinberger, Independent Director
A Washington, Independent Director
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Executive CFO
Michael Bodner, Global Recovery
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Mary Beckerle, Independent Director
Darius Adamczyk, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Hani Abouhalka, Company Digital
Ahmet Tezel, Group RD
Robert Decker, Controller Officer
Mathai Mammen, Executive Vice President Pharmaceuticals, R&D
Timothy Schmid, Executive MedTech
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer
James Swanson, Executive Vice President, Chief Information Officer
Hubert Joly, Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health
Jessica Moore, Vice Relations
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Celine Martin, Group CSS
Eugene Washington, Independent Director
Elizabeth Forminard, Executive Counsel
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Guy MD, Group EMEA
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Johnson Johnson Investors Sentiment

The influence of Johnson Johnson's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Johnson. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Johnson Johnson's public news can be used to forecast risks associated with an investment in Johnson. The trend in average sentiment can be used to explain how an investor holding Johnson can time the market purely based on public headlines and social activities around Johnson Johnson. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Johnson Johnson's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Johnson Johnson's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Johnson Johnson's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Johnson Johnson.

Johnson Johnson Implied Volatility

    
  19.64  
Johnson Johnson's implied volatility exposes the market's sentiment of Johnson Johnson stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Johnson Johnson's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Johnson Johnson stock will not fluctuate a lot when Johnson Johnson's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.106
Dividend Share
4.7
Earnings Share
5.2
Revenue Per Share
33.613
Quarterly Revenue Growth
0.073
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.